1 / 25

AMD Therapy: Where Are We Now and Where Are We Going?

AMD Therapy: Where Are We Now and Where Are We Going?. Program Goal. Anti-VEGF Agents for the Treatment of AMD. The CATT Study. The CATT Study: Safety Results Year 2. The CATT Study: Efficacy Results Year 2. The IVAN Study. The IVAN Study: Interim Results at Year 1. The VIEW1/2 Studies.

larue
Download Presentation

AMD Therapy: Where Are We Now and Where Are We Going?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. AMD Therapy: Where Are We Now and Where Are We Going?

  2. Program Goal

  3. Anti-VEGF Agents for the Treatment of AMD

  4. The CATT Study

  5. The CATT Study: Safety Results Year 2

  6. The CATT Study: Efficacy Results Year 2

  7. The IVAN Study

  8. The IVAN Study: Interim Results at Year 1

  9. The VIEW1/2 Studies

  10. The VIEW1/2 Study Results

  11. Case 1: A Treatment-Naive Patient

  12. Diagnostic Workup

  13. Issues to Address

  14. Considerations for Choosing Treatment

  15. Dosing

  16. Case 2: Patient With Treatment-Resistant AMD

  17. Treatment Approaches

  18. Future Developments

  19. Future Developments

  20. Abbreviations

  21. References

  22. References (cont)

  23. References (cont)

  24. References (cont)

More Related